Gout Therapeutics Global Market Report 2024

The gout therapeutics market size has grown rapidly in recent years. It will grow from $2.54 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 12.7%. The growth observed in the historic period can be attributed to factors such as the increased prevalence of gout, shifts in lifestyle and dietary patterns, elevated rates of high blood pressure and diabetes, the development of xanthine oxidase inhibitors, and initiatives focused on educating patients.

The gout therapeutics market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to increasing healthcare expenditure, advancements in drug delivery systems, the emergence of novel therapies, government initiatives aimed at chronic disease management, and the presence of patient advocacy and support groups. Major trends expected in the forecast period include innovative drug development, approvals for novel drugs, approaches in personalized medicine, the provision of telehealth services for gout management, and ongoing research in urate-lowering therapies.

The anticipated growth in the gout therapeutics market is expected to be driven by the rising occurrence of gout. Gout, characterized by inflammatory arthritis causing pain and swelling in joints, is effectively treated by gout therapeutics, providing relief from pain, swelling, and tenderness in affected joints. The increasing incidence of gout is poised to contribute to the market's growth. For instance, reports from the UK's National Health Service in September 2022 revealed a 20% increase in new gout cases recorded in British hospitals between 2021 and 2022, totaling 250,000 cases. Consequently, the upward trend in gout incidence is a significant driver for the growth of the gout therapeutics market.

The growing prevalence of obesity is anticipated to fuel the expansion of the gout therapeutics market in the years to come. Obesity, characterized by an abnormal accumulation of body fat, is considered a major risk factor for the onset and exacerbation of gout. Obesity can intensify the frequency and severity of gout attacks, posing challenges in their management. According to the World Health Organization's March 2022 report, over 1 billion individuals globally, including 340 million adolescents, 39 million children, and 650 million adults, are affected by obesity. The prevalence of obesity continues to rise, with WHO projections indicating that by 2025, 167 million adults and children will face health consequences due to being overweight or obese. Therefore, the increasing prevalence of obesity stands as a driving force for the gout therapeutics market.


Product innovation is a prominent trend gaining traction in the gout therapeutics market, with major companies actively engaged in developing innovative treatments to maintain their competitive edge. An example of such innovation is seen in the August 2022 launch of SYNB2081 by Synlogic Inc., a US-based pharmaceutical company. SYNB2081, a synthetic biotic, represents a novel drug candidate designed for gout treatment, specifically aimed at lowering uric acid levels. This development is the outcome of a collaborative research effort between Synlogic and Ginkgo, a US-based biotech company.

Major companies in the gout therapeutics market are focusing on the development of innovative products, such as corticotropin. Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a peptide hormone secreted by the anterior pituitary gland in response to low cortisol levels in the blood. An illustration of this is seen in the January 2022 launch of Purified Cortrophin Gel (Repository Corticotropin Injection USP) 80 U/mL by ANI Pharmaceuticals, Inc., a US-based pharmaceutical company. This gel, an adrenocorticotropic hormone (ACTH), is marketed by ANI's newly established rare illness business unit and is used in the treatment of chronic autoimmune conditions such as acute exacerbations of multiple sclerosis (MS) and gouty arthritis (GA), as well as excess urine protein due to nephrotic syndrome.

In December 2022, Innovent Biologics, a China-based biopharmaceutical company, and LG Chem Life Sciences, a US-based pharmaceutical company, forged a strategic collaboration and license agreement for LG Chem's Tigulixostat, intended for the chronic management of hyperuricemia in patients with gout disease. This partnership grants Innovent exclusive rights to develop and commercialize Tigulixostat in China for $95.5 million, encompassing a $10 million upfront payment. LG Chem stands to receive milestones and tiered royalties based on net product sales in China. Tigulixostat, a novel xanthine oxidase inhibitor, targets the reduction of uric acid in purine metabolism, showcasing a therapeutic intervention for gout.

Major companies operating in the gout therapeutics market report are AbbVie Inc., Sanofi-Aventis, AstraZeneca PLC, LG Chem Ltd., GlaxoSmithKline PLC, Takeda Pharmaceuticals Co. Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sandoz, Eisai Co. Ltd., Horizon Pharma PLC, Jiangsu HengRui Medicine Co. Ltd., Hikma Pharmaceuticals PLC, Swedish Orphan Biovitrum AB, JW Pharmaceutical Corp, Lannett Company Inc., BioCryst Pharmaceuticals Inc., Selecta Biosciences Inc., Rigel Pharmaceuticals Inc., Avion Pharmaceuticals LLC, Protalix BioTherapeutics Inc., Teijin Pharma Limited, Romeg Therapeutics LLC., CymaBay Therapeutics Inc., GeneScience Pharmaceuticals Co. Ltd., Shanton Pharma.

North America was the largest region in the gout therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gout therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of gout therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) are medications employed to reduce inflammation, relieve pain, and lower elevated body temperatures. Treatment options encompass xanthine oxidase inhibitors and uricosuria medications tailored for various disease conditions, including both acute and chronic cases. These therapeutics find application across various end-users, including hospitals, specialty clinics, and others.

The gout therapeutics market research report is one of a series of new reports that provides gout therapeutics market statistics, including gout therapeutics industry global market size, regional shares, competitors with a gout therapeutics market share, detailed gout therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gout therapeutics industry. This gout therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gout therapeutics market consists of the sales of allopurinol, benzbromarone, febuxostat, probenecid, and pegloticase drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.